Preview Mode Links will not work in preview mode

This Week in Cardiology

Feb 25, 2022

FDA approval of CardioMEMS, statins, VT storm, and fish oil and AF are the topics covered by John Mandrola, MD, in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I - Invasive Monitoring for HF

- FDA Expands Eligibility for CardioMEMS Heart Failure System

- Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

- Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial

II - Statin Use in Primary Prevention

- USPSTF Tweaks Primary Prevention Statin Recommendations in New Draft Guidance

- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication

- The Case Against Coronary Artery Calcium Scoring for Cardiovascular Disease Risk Assessment

III - VT-Storm

- Transcutaneous Magnetic Stimulation Promising Against VT Storm

- Effect of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm

IV - Fish Oil and AF risk

- Fish Oil Supplements May Increase the Risk for Atrial Fibrillation: What Does This Mean?

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact